March 28, 2025 03:35 PM EDT

Judge tosses Amgen's challenge to Colorado drug review board, says suit is 'too speculative'

Nicole DeFeudis

Editor

A federal judge on Friday dismissed Amgen’s lawsuit against Colorado’s drug affordability board and its call for a price cap on the company’s blockbuster autoimmune …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Judge tosses Amgen's challenge to Colorado drug review board, says suit is 'too speculative'

Nicole DeFeudis

Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects

Exclusive: SV Health debuts Parkinson's biotech with backing from AbbVie and others

Judge toss­es Am­gen's chal­lenge to Col­orado drug re­view board, says suit is 'too spec­u­la­tive'

Editor

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Judge tosses Amgen's challenge to Colorado drug review board, says suit is 'too speculative'